Condition: Non Small Cell Lung Carcinoma · Renal Cell Carcinoma · Sponsor: University of California, San Diego
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma. The main question it aims to answer is: What is the maximum dose of ruxolitinib that can be used safely in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma, and will it work? Participants will: Take drug ruxolitinib twice a day and keep a diary of when they take ruxolitinib at home; visit the clinic for infusions of retifanlimab every 4 weeks; visit the clinic for checkups and tests.
This description comes directly from the study's public registry record.
Rana McKay, MD · (858) 822-5354 · cancerCTO@health.ucsd.edu
Alexandrea Cronin · (858) 822-5354 · cancerCTO@health.ucsd.edu
Always discuss trial participation with your own doctor first.
| University of California, San Diego Moores Cancer Center | La Jolla, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07219576